Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience.
- Author:
Hyojung PARK
1
;
Dongryul OH
;
Yong Chan AHN
;
Hongryull PYO
;
Jae Myung NOH
;
Jong Mu SUN
;
Jin Seok AHN
;
Myung Ju AHN
;
Keunchil PARK
;
Hong Kwan KIM
;
Yong Soo CHOI
;
Jhingook KIM
;
Jae Ill ZO
;
Young Mog SHIM
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung carcinoma; Radiotherapy; Adjuvant chemotherapy
- MeSH: Carcinoma, Non-Small-Cell Lung*; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Radiotherapy; Recurrence
- From:Cancer Research and Treatment 2017;49(4):880-889
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities. MATERIALS AND METHODS: From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTx was delivered to 172 patients either as a consolidative or a sole modality (group II/III). RESULTS: During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively. CONCLUSION: The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.
